Zeit | Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
14.01. | Arcutis Biotherapeutics, Inc.: ZORYVE (Roflumilast) Topical Foam, 0.3% Clears Seborrheic Dermatitis in Individuals Who Previously Reported an Inadequate Response to Topical Steroids | 317 | GlobeNewswire (Europe) | New subgroup analysis from STRATUM study shows that individuals with an inadequate response, contraindication, or intolerance to steroids were 3.5 times more likely to achieve IGA Success with ZORYVE... ► Artikel lesen | |
14.01. | Arcutis Biotherapeutics, Inc.: Majority of Individuals with Atopic Dermatitis Improved with Arcutis' Roflumilast Cream 0.15% According to New Data from Phase 3 Program | 340 | GlobeNewswire (Europe) | Individual patient response data highlight 91.5% of individuals treated with roflumilast cream had a measurable improvement in Eczema Area and Severity Index (EASI) in just 4 weeks85% achieved measurable... ► Artikel lesen |
Suchbegriffe der letzen 24 h | Anzahl |
---|---|
EVOTEC | 1.682 |
NEL | 1.667 |
SUPER MICRO COMPUTER | 1.656 |
NVIDIA | 1.650 |
TUI | 1.484 |
BAYER | 1.336 |
RHEINMETALL | 1.000 |
RENK GROUP | 930 |
PROSIEBENSAT.1 | 912 |
VOLKSWAGEN | 735 |
AMAZON | 699 |
PALANTIR TECHNOLOGIES | 698 |
TESLA | 687 |
MICROSTRATEGY | 636 |
DEUTSCHE BANK | 585 |
PLUG POWER | 571 |
BASF | 565 |
BYD | 557 |
THYSSENKRUPP | 542 |
COMMERZBANK | 535 |
AIXTRON SE | 532 |
SAP | 507 |
MERCEDES-BENZ | 506 |
ALLIANZ | 493 |
DEUTSCHE TELEKOM | 473 |